Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 3/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28661395 | 0.79 | KRAS (0.38) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30485061 | 0.77 | JAK3 (0.37) | JAK3 | |
| SCHEMBL21423636 | 0.74 | POLB (0.52) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL21423710 | 0.74 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL4337331 | 0.74 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30622409 | 0.72 | GLRA1 (0.35) | ALDH1A1POLBJAK3JAK1 | |
| SCHEMBL25977010 | 0.72 | ALDH1A1 (0.31) | ALDH1A1POLBJAK3JAK1 | |
| SCHEMBL25367205 | 0.71 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL23011801 | 0.69 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL25781363 | 0.69 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208957-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208957-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | PIK3R5, PIK3R3, PIK3R1 | CHRNB2 4364/4885CHRNA4 4575/4885CHRNA7 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.